Premium
Significance of autocrine motility factor receptor gene expression as a prognostic factor in non‐small‐cell lung cancer
Author(s) -
Takanami Iwao,
Takeuchi Ken,
Watanabe Hideomi,
Yanagawa Takashi,
Takagishi Kenji,
Raz Avraham
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20011120)95:6<384::aid-ijc1068>3.0.co;2-d
Subject(s) - antibody , medicine , cd28 , cd19 , immunogenicity , t cell , immunology , cancer , cancer research , immune system
Autocrine motility factor receptor (AMF‐R) has been shown to play an important role in tumor cell migration, invasion and metastasis. We have detected AMF‐R expression in tissue specimens from patients with non‐small‐cell lung cancer (NSCLC) and have assessed their clinical characteristics. Using RT‐PCR and immunohistochemistry, we quantified the expression of AMF‐R in 47 patients with NSCLC who underwent curative tumor resection, to investigate the relationship between AMF‐R expression and clinicopathologic factors and prognosis. RT‐PCR results agreed well with the immunohistochemic results ( p < 0.0001). In 47 NSCLC patients, 34 (72.3%) samples were evaluated as having high AMF‐R gene expression. AMF‐R gene expression was significantly associated with lymph node metastasis and stage ( p = 0.0295 for lymph node metastasis, p = 0.0152 for stage). The overall survival rate for patients with high AMF‐R gene‐expressing tumors was significantly worse than for those whose tumors had low AMF‐R expression ( p = 0.0029). Multivariate analysis also showed that AMF‐R gene expression was significantly related to survival ( p = 0.0165). These data indicate that AMF‐R may contribute to tumor progression and that AMF‐R gene expression can serve as a useful prognostic marker in NSCLC. © 2001 Wiley‐Liss, Inc.